Find Funding Opportunities

-Purpose. The NIH invites applications for Countermeasures Against Chemical Threats (CounterACT) Advanced Development Cooperative Agreements (U01s).The overall mission of the CounterACT Research Network is to develop new and improved medical countermeasures against chemical threats (see http://www.ninds.nih.gov/funding/research/counterterrorism/index.htm). These include pulmonary agents such as chlorine, industrial chemicals such as cyanide, and nerve agents such as sarin.Unlike the previous CounterACT Funding Opportunity Announcements (FOAs), sulfur mustard research will not be supported by this announcement, research on diagnostic technologies will not be supported, and the focus will be on therapies that can be used after exposure to a chemical threat as opposed to pre-exposure prophylactic treatments.The expected outcome of each of these accelerated three-year projects is a lead compound or validated model for screening relevant therapeutics. -Mechanism of Support. This FOA will utilize the Research Project Cooperative Agreement (U01) award mechanism. -Funds Available and Anticipated Number of Awards.The NIH intends to commit approximately $2.5 million in Fiscal Year 2008 to fund 4-6 CounterACT research projects as cooperative agreements (U01s).Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

-Purpose. This purpose of this Funding Opportunity Announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose to develop and commercialize technologies for high throughput data acquisition and analysis that could aid the research fields of basic behavioral science, neuroscience or neuroAIDS relevant to the missions of the National Institute of Mental Health (NIMH) and National Institute of Neurological Disorders and Stroke (NINDS). -Mechanism of Support.This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-08-002, that solicits applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. -Funds Available and Anticipated Number of Awards. For this FOA, budgets up to $300,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $500,000 total costs per year and up to 3 years may be requested for Phase II. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

-The National Institute on Neurological Disorders and Stroke (NINDS) Research Education grant is a flexible and specialized mechanism designed to foster the development of neuroscience researchers through creative and innovative educational programs. Programs that focus on preparing diversity researchers in cross-disciplinary integration of neuroscience, including basic, translational, behavioral, prevention, clinical, and treatment research are encouraged. -Of particular interest are educational experiences that will attract, train, and further the career development of underrepresented biomedical scientists to improve the diversity of the research workforce relevant to the mission of NINDS.The NIH expects efforts to diversify the workforce to lead to the recruitment of the most talented researchers from all groups; such candidates include individuals from underrepresented racial and ethnic groups, individuals with disabilities, and individuals from disadvantaged backgrounds and will be referred to below as diversity research scientists or diversity trainees. -This mechanism of support is not to be used to substitute the Ruth L. Kirschstein National Research Service Award training and fellowship mechanisms and policies supported by the NIH.

-The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) invites applications from qualified investigators to participate in a multi-center cooperative research network to advance our understanding of urologic chronic pelvic pain syndromes (UCPPS) (this terminology is used solely for the purposes of this funding initiative) associated with the bladder (i.e. interstitial cystitis/painful bladder syndrome, IC/PBS) and the prostate gland (i.e. chronic prostatitis/chronic pelvic pain syndrome, CP/CPPS). This program will be named the Multidisciplinary Approach to the Study of Chronic Pelvic Pain (MAPP) Research Network. -The overall purpose of the MAPP Network is to conduct multi-disciplinary, collaborative, multi-site basic, translational, and clinical research addressing UCPPS. It is anticipated that these studies will increase our understanding of the pathophysiology, biologic and behavioral risk factors, natural history, and genetics of UCPPS. An important focus of the MAPP Network will be investigation of the biologic and behavioral relationships between IC/PBS and CP/CPPS and other frequently related symptom-based conditions. Related chronic pain syndromes of primary interest of this Network are fibromyalgia, irritable bowel syndrome, and chronic fatigue syndrome which have sufficient scientific evidence.Epidemiologic evidence is less compelling for vulvodynia and migraine headache, but these may be studied if adequate scientific justification is provided. The ultimate aim is to provide findings useful for development of future prevention or treatment strategies. -Studies conducted by the MAPP Network will be carried out by basic, translational, and clinical investigators who possess diverse but complementary expertise.Substantive collaboration among all investigators is required. Experienced investigators, investigators new to the field, and investigators with a broad range of expertise who may contribute substantially to the goals of this program, are strongly encouraged to apply.

-Purpose. Proteomics technologies and methods remain largely inadequate, particularly with respect to quantitative and real time measurements. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (SBIR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest. -Mechanism of Support.This FOA will utilize the SBIR (R43/R44) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-07-452, that solicits applications under the Small Business Technology Transfer (STTR) (R41/R42) grant mechanisms. -Funds Available and Anticipated Number of Awards. For this funding opportunity, budgets up to $200,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $400,000 total costs per year and up to 4 years may be requested for Phase II. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

-Purpose. Proteomics technologies and methods remain largely inadequate, particularly with respect to quantitative and real time measurements. This funding opportunity announcement (FOA) solicits Small Business Innovation Research (STTR) grant applications from small business concerns (SBCs) that propose the development of broadly applicable research tools that address the core technical challenges in proteomics and glycomics. This includes but is not restricted to robotics, sample preparation and pre-fractionation, analytical separations, gel and array imaging, quantitation, mass spectrometry, intelligent automated data acquisition, and improved informatics technologies. Technologies that address the unique needs of glycomics and clinical proteomics, described in Section II.I.1 (Research Objectives) are of particular interest. -Mechanism of Support.This FOA will utilize the STTR (R41/R42) grant mechanisms for Phase I, Phase II, and Fast-Track applications and runs in parallel with a FOA of identical scientific scope, PA-07-451, that solicits applications under the Small Business Innovation Research (SBIR) (R43/R44) grant mechanisms. -Funds Available and Anticipated Number of Awards. For this funding opportunity, budgets up to $200,000 total costs per year and time periods up to 2 years for Phase I may be requested. Budgets up to $400,000 total costs per year and up to 4 years may be requested for Phase II. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications.

Purpose. This Funding Opportunity Announcement (FOA) solicits research project grant (R01) applications focused on conducting efficacy and effectiveness trials of child abuse and neglect interventions.Specifically, this FOA solicits grant applications that include various levels of interventions.For those interventions that need preliminary research, applicants should consider additional mechanisms, which are used to establish efficacy, including the R21 and R34, as appropriate.However, given the public health need for children and families who experience the negative effects of child abuse and neglect, interventions in which preliminary developmental/exploratory work has already been undertaken, and pilot studies, or in some cases efficacy trials, have demonstrated positive change are strongly encouraged for R01 grant applications under this FOA.Of particular interest is the development of large scale trials designed to target either or both the victims or perpetrators of child abuse and neglect, including preventive interventions. Child abuse and neglect is a complex public health issue likely caused by a myriad of factors, including individual-, family-, and community-level elements.Thus, a research program focused on understanding and addressing these problems must necessarily draw upon interdisciplinary theories and approaches.One of the goals of this FOA is to bring together multi-disciplinary and translational perspectives encompassing basic biomedical, behavioral and social science research in mental health, physical health, public health and prevention, alcohol and substance abuse, neurology, injury, trauma and child development, to advance our knowledge of child abuse and neglect.Only projects proposing rigorous scientific research designs will be considered; service demonstrations or other types of service programs are not eligible for funding under this FOA. Mechanism of Support. This FOA will use the NIH Research Project Grant (R01) award mechanism.Applications for Exploratory/Developmental Grant (R21) and NIMH Clinical Exploratory/Developmental Research Grant (R34) are also sought for appropriate efficacy, exploratory, and treatment development studies. Applicants for the R21 and R34 award mechanisms should respond to the following FOAs for these mechanisms (NIH R21-PA-06-181; and the NIMH R34-PAR-06-248). Funds Available and Anticipated Number of Awards. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary.The total amount awarded and the number of awards will depend upon the mechanism numbers, quality, duration, and cost of the applications received.Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. Eligible Institutions/Organizations. Public/State Controlled Institution of Higher Education; Private Institution of Higher Education; Nonprofit with 501(c)(3) IRS Status (Other than Institution of Higher Education); Nonprofit without 501(c)(3) IRS Status (Other than Institution of Higher Education); Small Business; For-Profit Organization (Other than Small Business); State Government; U.S. Territory or Possession; Indian/Native American Tribal Government (Federally Recognized); Indian/Native American Tribal Government (Other than Federally Recognized); Indian/Native American Tribally Designated Organization; Non-domestic (non-U.S.) Entity (Foreign Organization); Hispanic-serving Institution; Historically Black Colleges and Universities (HBCUs); Tribally Controlled Colleges and Universities (TCCUs); Alaska Native and Native Hawaiian Serving Institutions; Regional Organization; Eligible Agencies of the Federal government; Faith-based or community-based organizations. Eligible Project Directors/Principal Investigators (PDs/PIs). Individuals with the skills, knowledge, and resources necessary to carry out the proposed research are invited to work with their institution/organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Number of Applications. Applicants may submit more than one application, provided each application is scientifically distinct. Renewals and Resubmissions.Applications can be renewed by competing for additional project periods.Applicants may submit a resubmission application, but such application must include an Introduction addressing the previous peer review critique (Summary Statement). Number of PDs/PIs.More than one PD/PI, or multiple PDs/PIs, may be designated on the application.

-The purpose of this funding opportunity is to provide support for investigative groups to conduct genome-wide association (GWA) genotyping and/or replication studies, using data and specimens from human subjects on whom information is available for conditions/traits of public health importance and relevant environmental exposures. It includes support for sharing the specimens and data and analyzing the resulting data as part of the NIH-wide Genes, Environment, and Health Initiative (GEI). -$1.8 million in FY 2008 funds have been committed to fund applications in response to this RFA. -It is anticipated that 2-4 awards will be made under this RFA. Awards are contingent on the availability of funds and the submission of a sufficient number of meritorious applications.

-Purpose. The National Institute on Drug Abuse (NIDA), the National Institute on Aging, the National Institute of Neurological Disorders and Stroke (NINDS), and the National Institute of Mental Health (NIMH), through the issuance of this Request for Applications (RFA), seeks to encourage broader uses of established PET/SPECT radioligands by reducing barriers to their wider distribution, and expanding their utility to the study of diseases or organs for which the radioligand has not previously been studied. Applications for this RFA should demonstrate a high degree of innovation and novelty with regard to the new uses for existing radioligands. Although there is no requirement for preliminary data, a clear scientific rationale is essential. Applications for this RFA are expected to propose multi-institutional collaborations between investigators who have the capacity for routine production of a given radioligand for human use, and investigators who lack access to the radioligand but wish to demonstrate the feasibility of an innovative use for the radioligand in a novel patient population. The primary focus of the proposal must be on human studies; animal studies are allowable only if required to obtain regulatory approval for the ligands. -Mechanism of Support. This Funding Opportunity Announcement (FOA) will utilize the NIH Phased Innovation Award (R21/R33) grant mechanism.  -Funds Available and Anticipated Number of Awards. This RFA has approximately $2.5M set aside to fund meritorious applications that address the goals of this solicitation. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. It is anticipated that between 8 - 10 proposals might be funded under this solicitation.

-This funding opportunity announcement (FOA) solicits new (type 1) and competitive renewal (type 2) applications for the support of Senator Paul D. Wellstone Muscular Dystrophy Cooperative Research Centers. Successful applicants will join a network of existing Centers to foster the translation of new scientific findings and technological developments into novel treatments for the muscular dystrophies. Each Center may contain a mixture of basic, translational, or clinical research, as long as efforts are directed toward the steps required for therapeutic development, including therapeutic target identification, characterization, and validation, development of diagnostics and biomarkers to characterize or stratify patient populations, in vitro assay development, animal model development and characterization, candidate therapeutic efficacy screening, preclinical therapeutic optimization and FDA-required activities leading to an investigational new drug (IND) application, clinical infrastructure and studies in support of a clinical trial, patient-oriented natural history studies, and early stage clinical trials for one or more types of muscular dystrophy. -Applicants should propose multi-disciplinary and collaborative studies that address one or more gaps in the therapeutic development pipeline for muscular dystrophy. Research problems should require substantial collaborative efforts to solve, and thus are best carried out in a center setting. -Centers should be designed to include the following components: one or more scientific project(s), an Administrative Core, a Scientific Research Resource Core with national impact, and a Research Training and Education Core.Applications may include additional core facilities within the overall budget cap (see below).